Phibro Animal Health Corporation

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2022, 2021

In its 2023 reporting, Phibro Animal Health Corporation disclosed greenhouse gas emissions of 47.9K tCO2e/year (2023). By scope: Scope 1: 31.9K tCO2e/year (2023); Scope 2: 16.0K tCO2e/year (2023). Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
47.9K tCO2e/year (2023)
2023
⚡
Renewable Energy
More than 50% of third-party sourced electricity for manufacturing from renewable sources (2023)
of total energy
💧
Water Usage
1.1M m3/year (2023) withdrawn 487919 m3/year (2023) discharged
2023
♻️
Waste
8.8K tons/year (2023) hazardous 16250 tons/year (2023) non-hazardous
2023
⚙️
Energy Use
939.6K GJ/year (2023)
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).31.9K tCO2e/year (2023)
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.16.0K tCO2e/year (2023)

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
202347.9K tCO2e/year (2023)
202243.1K tCO2e/year
202140.4K MT CO2e (2021)

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🌱 ESG Focus Areas

Environmental StewardshipSocial Responsibility and Well-BeingFair and Transparent Governance

⚠️ Challenges & Risks +

  • Outbreaks of animal diseases could significantly reduce demand for products or availability of raw materials.
  • Perceived adverse effects on human health linked to consumption of food derived from animals using Phibro's products.
  • Restrictions on the use of antibacterials in food-producing animals.
  • Potential FDA withdrawal of approval of Mecadox product.
  • Competition from large and small companies.
  • Negative effects of weather conditions and availability of natural resources.
  • Negative impacts of pandemics on business, financial results, and supply chain.
  • Climate change impacts on operations and customers' businesses.
  • Actions of regulatory bodies.
  • Consolidation of customer groups and emergence of large buying groups.

📋 Report Information

Reporting Period: 2023
Frameworks: SASB, GRI
Assurance: Third-party verification of data and calculation methodologies by a top environmental consulting firm.